$ONC

Rosenberg Aaron sold $362K of ONC

Rosenberg Aaron (Chief Financial Officer) sold 1,157 shares of BeOne Medicines Ltd. (ONC) at $312.72 ($0.36M total) on 2026-08-03.

Original reporting
SEC EDGAR · Rosenberg Aaron
Published Aug 5, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CFO, including date, share count, price, and post-transaction holdings.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no accompanying fundamental update in the text.

03

What to watch

The filing shows holdings after the transaction are 0 shares, but the article does not provide prior grant history, option exercises, or whether other insiders are buying, which limits inference.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-05, covering a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines CFO Aaron Rosenberg sold 1,157 shares in an open-market transaction at $312.7150 on 2026-08-03, per Form 4.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no earnings, guidance, deal, or operational change. Insider sales are common and the disclosed size is not described as extraordinary beyond the stated transaction.

Market effects

Minimal. Single-company insider sale does not imply sector-wide regulatory or clinical changes.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or tax liquidity, and the absence of a 10b5-1 plan in the text does not prove wrongdoing or a negative outlook.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ticker ONC).

  • Aaron Rosenberg

    Chief Financial Officer who sold 1,157 shares in an open-market transaction.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.